Adiponectin (ADP), a modulator of insulin actions, recently became an attractive therapeutic tool. We present here the effect of the first‐in‐class ADP receptor agonist (ADP355) on weight gain and biomarker patterns associated with long term high fat diet (HFD).Adult Sprague‐Dawley (SD) rats (n=23) were fed HFD (60% cal from fat) ad‐libitum for 15 weeks. ADP355 at 0.5mg/kg/dose, or saline was administered intraperitoneally every other day (n=3 each); weight gain, food intake, glucose (Glc) levels and blood biomarkers were assessed weekly. C‐reactive protein, glucagon, IL‐6, TNFα, amylin, insulin and leptin levels were measured by a multiplexed bead‐specific Luminex assay. The assays included 3 randomly selected matched controls. Results were assessed by student t‐test.After 15 weeks of treatment, the ADP355 group exhibited reduced weight gain (P<0.009), lower Glc levels (P=0.02), n=20, and significantly decreased glucagon (P<0.015) levels relative to control. While leptin levels increased, TNFα and amylin levels decreased significantly in the control group (P<0.002 for all). In the ADP355 group, leptin expression maintained a modestly increasing trend, however, no change was observed in the TNFα or amylin levels. In HFD fed SD rats, stimulation of the ADP receptor might be beneficial for weight gain prevention; however, our data do not support an anti‐inflammatory activity of ADP355 administration.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.